1Fidel PL Jr. Immunity in vaginal candidiasis[J]. Curr Opin Infect Dis,2005, 18(2): 107-111.
2Barousse MM, Van Der Pol BJ, Fortenberry D, et al. Vaginal yeast colonisination, prevalence of vaginitis, and associated local immunity in adolescent[J]. Sex Transm Infect, 2004, 80(1): 48-53.
3Fidel PL Jr, Barousse M, Louvev V, et al. Local immune responsiveness following intravaginal challenge with candida antigen in adult women at different stages of the menstrual cycle [J]. Med Mycol,2003, 41(2): 97-109.
4Ibrahim AS, Spellberg BJ, Avenissian V, et al. Vaccination with recombinant N-terminal domain of Alslp improve survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral immunity[J]. Infect Immun, 2005, 73(2): 999-1005.
5Ann D, Charles HM, Susan MF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virusinfected women: Risk Factors and Severity [J]. Obstet Gynecol,2003, 101(3): 548-556.
6LeBlanc DM, Barousse MM, Fidel PL Jr. Role for dendritic cells in immunoregulation during experimental vaginal candidiasis [J ]. Infect Immun, 2006, 74(6): 3213-3221.
7Moragues MD, Omaetxebarria MJ, Elguezabal N, et al. A monoclonal antibody directed against a candida albicans cell wall mannoprotein exerts three anti-C.albicans activities[J]. Infect Irmnun, 2003,71(9): 5273-5279.
8Culter JE. Defining criteria for anti-mannan antibodies to protect against candidiasis[J]. Curr Mol Med, 2005, 5(4): 383-392.
9Kosonen J, Rantala A, Little CH, et al. Increased levels of candida albicans mannan-specific T-cell-derived antigen binding molecules in patients with invasive candidiasis [J]. Clin Vaccine Immunol, 2006,13(4): 467-474.
10Taylor BN, Staib P, Binder A. Profile of candida albicans-secreted aspartyl proteinase elicited during vaginal infection [J]. Infect Immun, 2005, 73(3): 1828-1835.
